HRP20060362A2 - Method for the purification of albumin conjugates - Google Patents

Method for the purification of albumin conjugates

Info

Publication number
HRP20060362A2
HRP20060362A2 HR20060362A HRP20060362A HRP20060362A2 HR P20060362 A2 HRP20060362 A2 HR P20060362A2 HR 20060362 A HR20060362 A HR 20060362A HR P20060362 A HRP20060362 A HR P20060362A HR P20060362 A2 HRP20060362 A2 HR P20060362A2
Authority
HR
Croatia
Prior art keywords
albumin
albumin conjugates
conjugates
purification
solution
Prior art date
Application number
HR20060362A
Other languages
English (en)
Croatian (hr)
Inventor
Bousquet-Gagnon Nathalie
Quraishi Omar
P. Bridon Dominique
Original Assignee
Conjuchem Biotechnologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35196920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20060362(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Biotechnologies Inc. filed Critical Conjuchem Biotechnologies Inc.
Publication of HRP20060362A2 publication Critical patent/HRP20060362A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/303—Extraction; Separation; Purification by precipitation by salting out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HR20060362A 2004-04-23 2006-10-23 Method for the purification of albumin conjugates HRP20060362A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56522804P 2004-04-23 2004-04-23
PCT/CA2005/000614 WO2005103087A1 (fr) 2004-04-23 2005-04-22 Procede de purification de conjugues d'albumine

Publications (1)

Publication Number Publication Date
HRP20060362A2 true HRP20060362A2 (en) 2007-03-31

Family

ID=35196920

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20060362A HRP20060362A2 (en) 2004-04-23 2006-10-23 Method for the purification of albumin conjugates

Country Status (25)

Country Link
US (3) US7307148B2 (fr)
EP (3) EP1745078B1 (fr)
JP (1) JP2007535507A (fr)
CN (1) CN1956998B (fr)
AT (2) ATE473244T1 (fr)
AU (1) AU2005235634B2 (fr)
BR (1) BRPI0510117A (fr)
CA (1) CA2564031A1 (fr)
DE (2) DE602005014969D1 (fr)
DK (2) DK1745078T3 (fr)
EA (1) EA011168B1 (fr)
ES (2) ES2347902T3 (fr)
HK (2) HK1096102A1 (fr)
HR (1) HRP20060362A2 (fr)
IL (1) IL178369A0 (fr)
MA (1) MA28587B1 (fr)
MX (1) MXPA06012260A (fr)
NO (1) NO20065037L (fr)
PL (2) PL1745078T3 (fr)
PT (2) PT1745078E (fr)
RS (1) RS20060578A (fr)
SI (2) SI1745078T1 (fr)
TN (1) TNSN06340A1 (fr)
WO (1) WO2005103087A1 (fr)
ZA (1) ZA200608475B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
CA2372338A1 (fr) * 1999-05-17 2000-11-23 Conjuchem Inc. Peptides hybrides inhibiteurs a action prolongee des infections virales
EA003922B1 (ru) * 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
WO2002066511A2 (fr) * 2001-02-16 2002-08-29 Conjuchem Inc. Peptide 2 de type glucagon (glp-2) de longue duree utilise dans le traitement des maladies et troubles gastro-intestinaux
ATE412667T1 (de) * 2001-05-31 2008-11-15 Conjuchem Biotechnologies Inc Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
AU2005240680A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
WO2007053946A1 (fr) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Procede de traitement du diabete et/ou de l'obesite en reduisant les effets secondaires nauseeux au moyen d'un peptide insulinotrope conjugue a de l'albumine
MX2008008076A (es) * 2005-12-22 2008-11-28 Conjuchem Biotechnologies Inc Procesos para la produccion de conjugados preformados de albumina y un agente terapeutico.
EP2114437A2 (fr) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Peptides du facteur libérateur de corticotrophine modifiés et leurs utilisations
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
WO2008144584A2 (fr) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Dérivés d'acide cystéique de peptides antiviraux
WO2008157824A2 (fr) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Conjugués de peptides thrombopoïétiques
WO2009075859A2 (fr) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation de conjugués de peptides insulinotropes
WO2009110952A2 (fr) * 2007-12-31 2009-09-11 New York University Contrôle de la fusion de membrane hôte virale avec des hélices artificielles à base de succédané de liaison hydrogène
WO2009121884A1 (fr) 2008-04-01 2009-10-08 Novo Nordisk A/S Conjugués insuline-albumine
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
PT3092010T (pt) * 2014-01-10 2018-09-28 Synthon Biopharmaceuticals Bv Método para purificação de conjugados anticorpo-fármaco ligados por cys
WO2015116988A2 (fr) * 2014-01-31 2015-08-06 Counterpoint Health Solutions, Inc. Métabolites liés par des liaisons covalentes utilisables en tant que biomarqueurs
WO2016065052A1 (fr) * 2014-10-22 2016-04-28 Extend Biosciences, Inc. Conjugués insuline vitamine d
CN105111306A (zh) * 2015-08-28 2015-12-02 北京工业大学 美洲短吻鳄白蛋白的分离方法
JP7123399B2 (ja) 2016-03-24 2022-08-23 ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド タクロリムスのコンジュゲート、その組成物およびその使用
SG11202002563WA (en) 2017-09-28 2020-04-29 Hanmi Pharmaceutical Co Ltd Long-acting conjugates of glp-2 derivatives
CN108840922A (zh) * 2018-06-04 2018-11-20 河北常山生化药业股份有限公司 分离白蛋白非结合物、白蛋白结合物和小分子化合物的方法
CN108977423A (zh) * 2018-08-17 2018-12-11 集美大学 一种从猪肺中分离提纯血管紧张素转化酶的方法
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
CN109721653B (zh) * 2019-03-05 2023-02-03 嘉兴学院 一种胰高血糖素样肽-1片段类似物及其应用
WO2021175275A1 (fr) * 2020-03-06 2021-09-10 昆山新蕴达生物科技有限公司 Albumine modifiée de manière hydrophobe, son procédé de préparation et son application
US20230218773A1 (en) * 2020-04-30 2023-07-13 Board Of Regents, The University Of Texas System Albumin drug conjugates and use thereof for the treatment of cancer
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
US4251631A (en) 1978-02-23 1981-02-17 Research Products Rehovot Ltd. Cross-linked enzyme membrane
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4678671A (en) * 1981-12-15 1987-07-07 Cordis Europa N.V. Conjugates of anticoagulant and protein
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4745100A (en) 1985-05-14 1988-05-17 Eye Research Institute Of Retina Foundation Stimulation of tear secretion
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4859604A (en) 1987-08-27 1989-08-22 Ampor, Inc. Composition for stabilization of diagnostic reagents
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5725804A (en) 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
DE69226077T2 (de) 1991-04-05 1998-12-03 Genentech, Inc., South San Francisco, Calif. PLAETTCHENAGGREGATIONSINHIBITOREN MIT HOHER SPEZIFIZITAET ZUM GP IIbIIIa
US5103233A (en) 1991-04-16 1992-04-07 General Electric Co. Radar system with elevation-responsive PRF control, beam multiplex control, and pulse integration control responsive to azimuth angle
CA2131528C (fr) 1992-03-05 2004-07-13 Philip E. Thorpe Agents diagnostiques et/ou therapeutiques cibles pour les cellules endotheliales neovasculaires
JPH07102148B2 (ja) * 1992-05-20 1995-11-08 株式会社ミドリ十字 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物
US5807827A (en) 1992-06-12 1998-09-15 Des-Tyr Dynorphin Partnership Des-Tyr dynorphin analogues
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US20020018751A1 (en) 1993-10-15 2002-02-14 BRIDON Dominique P. Cellular and serum protein anchors for diagnostic imaging
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK145493D0 (da) 1993-12-23 1993-12-23 Dako As Antistof
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
CA2187322A1 (fr) 1994-04-07 1995-10-19 Israel Rubinstein Polypeptide intestinal vasoactif
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
DK0699687T3 (da) * 1994-08-31 2004-04-26 Mitsubishi Pharma Corp Fremgangsmåde til oprensning af rekombinant humant serumalbumin
US5939390A (en) 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US6767887B1 (en) 1996-06-05 2004-07-27 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
AU4351897A (en) 1996-09-16 1998-04-02 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ATE366584T1 (de) 1996-11-12 2007-08-15 Novo Nordisk As Verwendung von glp-1 peptiden
WO1998021234A2 (fr) * 1996-11-15 1998-05-22 Genentech, Inc. Purification de neurotrophines
DK1629849T4 (en) 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
US6723530B1 (en) 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
ATE406577T1 (de) 1997-11-07 2008-09-15 Conjuchem Biotechnologies Inc Methoden zum screening von affinitätsmarker- bibliotheken
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
DE69812727D1 (de) * 1997-11-07 2003-04-30 Conjuchem Inc Opioid-konjugate mit endogenen Trägerproteinen
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US20030170250A1 (en) 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
AU770712B2 (en) 1999-01-14 2004-02-26 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
CN101181236A (zh) 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
US7399489B2 (en) * 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EA003922B1 (ru) 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
CA2372338A1 (fr) * 1999-05-17 2000-11-23 Conjuchem Inc. Peptides hybrides inhibiteurs a action prolongee des infections virales
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
SI1133312T1 (sl) 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
DE19932782A1 (de) * 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US20020003999A1 (en) * 2000-03-09 2002-01-10 Claus Bonde Discharge and stacker device
EP1278544A4 (fr) * 2000-04-12 2004-08-18 Human Genome Sciences Inc Proteines hybrides d'albumine
JP4881533B2 (ja) 2000-05-19 2012-02-22 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１を用いた急性冠状動静脈症候群の治療
JP4480329B2 (ja) 2000-10-20 2010-06-16 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１ペプチドによる冬眠心筋および糖尿病性心筋症の治療
EP1390061A2 (fr) 2000-12-13 2004-02-25 Eli Lilly And Company Regime de traitement chronique utilisant des peptides insulinotropiques du type glucagon
EA006484B1 (ru) * 2001-02-02 2005-12-29 Конджачем, Инк. Долгоживущие производные рилизинг-фактора гормона роста
WO2002066511A2 (fr) * 2001-02-16 2002-08-29 Conjuchem Inc. Peptide 2 de type glucagon (glp-2) de longue duree utilise dans le traitement des maladies et troubles gastro-intestinaux
ATE412667T1 (de) 2001-05-31 2008-11-15 Conjuchem Biotechnologies Inc Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
SE526227C2 (sv) * 2002-05-15 2005-08-02 North China Pharmaceutical Group Metod för rening av rekombinant humant serumalbumin
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
RU2006120077A (ru) * 2003-12-18 2008-01-27 Ново Нордиск А/С (DK) Аналоги глюкагоноподобного пептида-1 (glp-1), связанные с альбуминоподобными агентами

Also Published As

Publication number Publication date
ES2328591T3 (es) 2009-11-16
US20120022234A1 (en) 2012-01-26
DK2100904T3 (da) 2010-11-08
EP2100904A1 (fr) 2009-09-16
ATE433999T1 (de) 2009-07-15
WO2005103087A1 (fr) 2005-11-03
US20080146783A1 (en) 2008-06-19
DE602005014969D1 (de) 2009-07-30
US7307148B2 (en) 2007-12-11
SI2100904T1 (sl) 2010-10-29
EP2230257A1 (fr) 2010-09-22
PL1745078T3 (pl) 2009-12-31
EP1745078A1 (fr) 2007-01-24
PT1745078E (pt) 2009-09-17
ZA200608475B (en) 2007-11-28
NO20065037L (no) 2007-01-11
DK1745078T3 (da) 2009-10-26
RS20060578A (en) 2008-11-28
CN1956998A (zh) 2007-05-02
SI1745078T1 (sl) 2009-12-31
PT2100904E (pt) 2010-09-24
HK1096102A1 (en) 2007-05-25
CA2564031A1 (fr) 2005-11-03
TNSN06340A1 (en) 2008-02-22
MXPA06012260A (es) 2006-12-15
EP1745078A4 (fr) 2007-08-01
EA011168B1 (ru) 2009-02-27
HK1136305A1 (en) 2010-06-25
CN1956998B (zh) 2012-12-12
EA200601959A1 (ru) 2007-04-27
ES2347902T3 (es) 2010-11-22
JP2007535507A (ja) 2007-12-06
MA28587B1 (fr) 2007-05-02
IL178369A0 (en) 2007-02-11
PL2100904T3 (pl) 2011-05-31
ATE473244T1 (de) 2010-07-15
BRPI0510117A (pt) 2007-09-25
AU2005235634B2 (en) 2011-10-20
US20050267293A1 (en) 2005-12-01
EP1745078B1 (fr) 2009-06-17
AU2005235634A1 (en) 2005-11-03
EP2100904B1 (fr) 2010-07-07
DE602005022239D1 (de) 2010-08-19

Similar Documents

Publication Publication Date Title
IL178369A0 (en) Method for the purification of albumin conjugates
JP2005206602A5 (fr)
WO2007109163A3 (fr) Tampon de lavage et procédé d'utilisation correspondant
DK1156835T3 (da) Fremgangsmåde til radiomærkning af proteiner med Yttrium-90
TW200740839A (en) Methods of purifying Fc region containing proteins
EP1568710A3 (fr) Procédé de purification des anticorps
WO2007060336A3 (fr) Motorisation pour pieton
PL1841863T3 (pl) Sposób oczyszczania czynnika VII
FI1888636T4 (fi) Vasta-aineiden puhdistusmenetelmä
WO2005100394A3 (fr) Proteine hybride fc/interleukine-15 purifiee et son procede de preparation
MX2009005012A (es) Una forma pura de rapamicina y procedimiento para la recuperacion y purificacion de la misma.
ATE461199T1 (de) Verfahren zur trennung und reinigung von hydrocodon durch präparative chromatographie
WO2007001834A3 (fr) Procedes et appareils permettant d'ameliorer la sensibilite de l'electrophorese capillaire de zone
WO2002101021A3 (fr) Purification de la serum-albumine humaine
MX342922B (es) Purificacion de insulina.
DK1064066T3 (da) Adsorptionschromatografi
DE602004018674D1 (de) Grosstechnisches verfahren zur abtrennung und aufreinigung von fentanyl durch präparative umkehrphasenchromatographie
FI894235A (fi) Foerfarande foer aotervinning av proteiner ur en loesning.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110324

Year of fee payment: 7

OBST Application withdrawn